BlogHotel.orgAccueil | Créer un blog | Imprimer la page Imprimer | Blog hasard Au hasard | Chercher des blogs Rechercher | Entrer dans le chat du blog Chat | | Jeux Jeux | Adminitration et édition du Blog Manager

shinenewstop Accueil | Profil | Archives | Amis
shinenewstop

As-needed budesonide-formoterol bests albuterol for exacerbation prevention in mild asthma 5/11/2019
Single combination inhaler treatment with budesonide-formoterol on an as-needed basis, compared with albuterol, more than halved the risk for severe asthma attacks in patients with mild asthma, according to the results of the Novel START trial presented at the American Thoracic Society International Conference.wisepoqder Formoterol

“We undertook a real-world study and the question we wanted to ask was that in adults with intermittent and mild asthma who were treated with reliever therapy alone — step 1 treatment — what is the efficacy of a combination inhaled corticosteroid and fast-onset long-acting beta-agonist inhaler used as a reliever alone with two other therapeutic regimens. The first was a continuation of step 1 therapy with reliever therapy alone and the other was a step up to step 2 therapy with maintenance inhaled corticosteroids and reliever therapy, as recommended by asthma guidelines,” Richard Beasley, DSc, from the Medical Research Institute of New Zealand and the Capital and Coast District Health Board, said during his presentation of the data.

The 52-week, open-label, randomized, parallel-group, controlled trial included 668 patients with mild asthma who were randomly assigned one of three treatments: two inhalations of albuterol 100 µg (Ventolin, GlaxoSmithKline) from a pressurized metered-dose inhaler as needed for asthma symptoms; one inhalation of budesonide 200 μg (Pulmicort Turbuhaler, AstraZeneca) taken twice daily plus as-needed albuterol; or one inhalation of budesonide 200 μg/formoterol 6 μg (Symbicort Turbuhaler, AstraZeneca) as needed.

Of 675 patients enrolled from 2016 to 2017 in New Zealand, Australia, United Kingdom and Italy, 668 were included in the analysis. To qualify for inclusion, patients had to be 18 to 75 years of age; a short-acting beta agonist (SABA) had to be the sole asthma therapy in the previous 3 months; and they had to report use of the SABA on at least two occasions in the last 4 weeks, but on average no more than two occasions per day, in the previous 4 weeks.
The primary outcome was annualized asthma exacerbation rates per patient. Exacerbations were characterized as worsening asthma that led to urgent medical care consultation, a prescription for systemic glucocorticoids or an episode of high beta-2-agonist use, which was defined as use of albuterol more than 16 times or the use of budesonide-formoterol more than eight times during 24 hours.

Poster un Commentaire

Entry 4052 of 5390
Précédent | Suivant

Blog suivant >> Signaler un abus? Haut de page